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Abstract: Lemon (Citrus limon (Linn) Burm. f) is a plant that has efficacy as antiplatelet. Flavonoids in lemon 
potentially obstruct COX-1 (Cyclooxygenase-1) receptor which has an important role in increasing 
thromboxane A2 in the process of ischaemic stroke. This research aims at looking for flavonoids activity 
from citrus lemon which is expected to be the antiplatelet drug candidates. The method used in this research 
was the molecular docking method using Autodock Vina and Pymol software programs. The results showed 
that the value of ΔG binding affinity Aspirin as the standard ligand was -6,5 kcal/mol and lemon flavonoid 
derivatives that have the lowest ΔG binding affinity value was on Neohesperidin -15,4 kcal/mol and Rutin -
15,3 kcal/mol. This research shows that Neohesperidin and Rutin in lemon can be used as drug candidate of 
antiplatelet in ischaemic stroke disease. 
1 INTRODUCTION 
Stroke is the third most common disease after heart 
disease and cancer. According to the World Health 
Organization (WHO), the definition of stroke is a 
rapidly growing clinical sign of focal (or global) 
brain dysfunction, with symptoms that last for 24 
hours or more, can cause death, with no cause other 
than vascular. Stroke is characterized by a sudden 
loss of blood circulation to the brain area resulting in 
a neurological deficit (Gund et al., 2013). In general, 
strokes are classified as ischaemic and hemorrhagic. 
Ischaemic stroke is an ischaemic brain tissue arising 
from a blockage in the cervical vascular blood 
vessels or brain tissue hyperfusion by various factors 
such as atherothrombosis, embolism, or 
hemodynamic instability (Chung and Caplan, 2007).  
Stroke is the third leading cause of death in the 
United States and Britain after heart disease and 
cancer, and the main cause of adult disability. In the 
United States, more than 160,000 adult Americans 
die of strokes every year. In Europe, around 650,000 
people died from strokes. In the United States, 
people who report strokes over 65 years (Gund et 
al., 2013). According to the latest data from Riset 
Kesehatan Dasar in 2013, the number of stroke 
patients in Indonesia in 2013 based on the diagnosis 
of Health Workers is estimated to be 1,236,825 
people (7.0 ‰), whereas based on diagnosis 
symptoms are estimated as many as 2,137,941 
people (12.1 ‰) (Balitbang, 2013). 
Antiplatelet therapy is an important long-term 
treatment for all patients at risk of atherothrombosis 
such as ischaemic stroke. A comparison of some 
antiplatelet drugs statistically indicated a significant 
difference in outcomes (Shinohara et al., 2010). 
Strong platelet function inhibitors have been 
developed in recent years with different drug-action 
mechanisms, because when combined the effects are 
additive or even synergistic (Ringleb et al., 2011). 
These antiplatelet drugs are classified into several 
groups based on their mechanism of action, namely 
inhibition of prostaglandin synthesis (aspirin), 
inhibition of ADP-induced platelet aggregation 
(clopidogrel, prasugrel, ticlopidine), and blockade of 
the receptor glycoprotein IIb/IIIa in platelets 
(abciximab, tirofiban, and eptifibatide) (Ringleb et 
al., 2011). However, these drugs can cause serious 
side effects for users such as gastrointestinal 
bleeding, leukopenia, and thrombocytopenia 
(Ringleb et al., 2011). Because of the side effects of 
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 these drugs, herbal medicine is also an option for 
patients.  
 Indonesia has a wealth of herbs, one of which 
is lemon (Citrus limon (Linn) Burm F.). One of the 
compounds in lemon that is thought to be potential 
as an antiplatelet is flavonoids. Based on studies that 
have been conducted, lemon plants are known to 
have activity as an anticoagulant and antiplatelet in 
vitro/in vivo (Riaz et al., 2014). Flavonoids are one 
type of antioxidant that can inhibit adhesion, 
aggregation and platelet secretion (Retnaningsih et 
al. 2007). The ability of flavonoids to inhibit platelet 
aggregation is caused by the flavonoid inhibiting the 
metabolism of arachidonic acid by cyclooxygenase 
enzyme, thus reducing the amount of thromboxane 
A2 (TXA2) production and platelet aggregate 
production causing blood vessel blockage 
(Middleton et al., 2000). 
Cyclooxygenase (COX) is a functional enzyme 
bound to the membrane acting to catalyze two 
important stages in the formation of prostanoid, 
cyclooxygenation, and peroxidation reaction. The 
cyclooxygenation reaction stage is the stage at which 
COX conducts a cyclization process and the addition 
of two oxygen molecules to arachidonic acid to form 
prostaglandin G2 (PGG2). The peroxidation stage is 
the reduction stage of PGG2 into an unstable 
endoperoxide compound called prostaglandin H2 
(PGH2). There are two main isoforms of the 
cyclooxygenase enzyme, cyclooxygenase-1 (COX-
1) and cyclooxygenase-2 (COX-2). COX-1 is 
expressed continuously and has a function as a 
regulator of homeostasis in the function of 
protecting the gastric mucosa, maintaining platelet 
integrity, and maintaining the function of renal 
perfusion. COX-2 plays a role in pathologies such as 
inflammation, pain, and cancer (Claria, 2003). 
Molecular docking is a device that can be used to 
study the interactions that occur from a molecular 
complex. Molecular docking helps in studying drug 
or ligand interactions with receptors or proteins. 
Molecular docking is conducted by identifying the 
corresponding active site of the receptor/protein, 
obtaining the best geometry of the receptor ligand 
and calculating the interaction energy of each 
different ligand for designing a more effective 
ligand. To perform molecular docking, the first thing 
required is a three-dimensional structure of ligand 
and receptor. Virtual screening is a computational 
technique in the design of new computer-based 
drugs (in silico) to identify the structures most likely 
to bind to a targeted drug, usually a protein or 
enzyme receptor (Mukesh and Rakesh, 2011). 
2 MATERIALS AND METHODS 
2.1 Materials 
The tool used in this research was hardware and 
software. Hard performances were equipped with 
AMD E1-2100 APU with Radeon ™ HD Graphics 
CPU GHz processor, 2GB RAM, and Microsoft 
Windows 7 Ultimate 64-bit operating system, 24-
inch Hp® Monitor, and Bolt® modem for internet 
access. The software programs were equipped with 
the MGL Tools 1.5.6 Package consisting of 
Autodock Vina, Autodock Tools, Pymol (DeLano 
Scientific LLC.),  Discovery Studio 4.5 Client, CLC 
Drug Discovery Workbench 2.5, Chem office 2010, 
Protein Data Bank (http://www.rcsb.org/pdb). 
The material used was the 3D structure of the 
platelet receptor that was downloaded from Protein 
Data Bank which has formatted .pdb,i.e. 
prostaglandin H2 synthase-1 (PDB ID: 1CQE) and 
3D structure used was flavonoid derived compound 
among others were eriocitrin, hesperidin, 
neohesperidin, diosmin, rutin, luteolin, nobiletin, 
sinensetin, and tangeritin (Molina et al., 2010). 
 
2.2 Methods 
Preparation of Prostaglandin H2 Synthase-1 (COX-
1) structure was conducted by downloading the 
COX-1 receptor macromolecule from the Protein 
Data Bank from http://www.rcsb.org/pdb formatted 
from .pdb website to .pdb. Cavity must be 
determined to find the residues in the receptor. The 
cavity determination was performed using the 
offline CLC Drug Discovery Workbench 2.5 
software that was downloaded from 
http://www.clcbio.com/products/clc-drug-discovery-
workbench/. Receptor macromolecules were 
separated from solvents and ligands or non-standard 
residues. The separation of macromolecules from 
unnecessary molecules was done using the 
Discovery Studio 4.0 program. The result of the 
separation was saved in .pdb format. The design of 
the ligand structure of the flavonoid derived 
compound consists of eriocitrin, hesperidin, 
neohesperidin, diosmin, rutin, luteolin, nobiletin, 
sinensetin, and tangeritin were downloaded from the 
PubChem site (http://pubchem.ncbi.nlm.nih.gov./). 
The docking file preparation was conducted by 
using Autodock Tools that was optimized by setting 
the number of action torsion and converting the 
format to .pdbqt. While the receptor preparation was 
being conducted by adding hydrogen polar, the grid 
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 box was set to know the position of the binding site 
and the format was changed to .pdbqt. This file was 
saved in a single folder in the C: drive on the 
computer. Molecular Docking Process was 
conducted using Autodock Vina. Ligands and 
receptor that were already in drive C: copied and 
converted in the form of notepad were saved with a 
conf.txt name, Autodock Vina was executed with 
command prompt program. 
Molecular docking analysis was done by looking 
at the free energy value of binding docking results, 
viewed at the output in log.txt format. The selected 
ligand-receptor complex was the complex which has 
the lowest free binding energy value for further 
analysis. The interaction between receptor and 
ligand can be observed in Pymol software 
3 RESULTS AND DISCUSSION 
The macromolecule that was used as the docking 
target was the Cyclooxygenase-1 enzyme (COX-1). 
COX-1 was downloaded from the Protein Data 
Bank. The PDB ID of COX-1 used was 1CQE 
which has been used as a reference in predicting 
antiplatelet activity based on previous research (Wu 
et al., 2007). 1CQE consisted of 580 amino acid 
residues. The 1CQE structure was downloaded from 
the RCSB site with the format .pdb. 
Cyclooxygenase-1 (COX-1) downloaded from the 
RCSB must be cleaned using the offline Discovery 
Studio 4.5 software because the receptor on RCSB is 
holoprotein, which contains many ligands in the 
receptor. The reason for the cleansing was to remove 
the original disturbing ligands and water attached to 
the receptor to speed up the docking process. 
Molecular docking is carried out on the specific 
region of the target protein, which is to be a binding 
site. The location of this site is based on the ligand 
or cofactor position co-crystallized with the structure 
of the target protein, or the position of the amino 
acids known for the binding position. 
To get the cyclooxygenase-1 receptor inhibitory 
effect, it must first recognize the residues that form 
cavity and pocket in the target (receptor). The cavity 
is a substance that is owned by the receptor. The 
pocket is a space inside the cavity as access to the 
bond between the ligand and the receptor, resulting 
in the expected effect. Cavity search was carried out 
using the CLC Drug Discovery Workbench 2.5 
software located at the site 
http://www.clcbio.com/products/clc-drug-discovery-
workbench/ (Glaab 2015). CLC Drug Discovery 
Workbench 2.5 is a software managed by CLC Bio 
A QIAGEN Company. This software can detect 
bindings on receptors through the programs 
provided. 
Usually, more than one cavity is found in the 
target receptor. Therefore, it was necessary to 
evaluate the cavity to saw the possibility of the 
cavity being a binding site that actually used the 
CLC Drug Discovery Workbench 2.5 software. In 
the search for COX-1 cavity receptors, many 
cavities were detected in the COX-1 receptor regions 
(Figure 1). It was necessary to do cavity evaluation 
by setting a binding site on the Drug Discovery 
Figure1: Results of COX-1 receptor site binding detection (CLC Drug Discovery Software). Description: Areas marked 
with green spots are cavity areas. The area in the white circle is the actual cavity as a binding site on the COX-1 receptor. 
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 Workbench 2.5 CLC work program. After cavity 
evaluation, the COX-1 receptor area that had been 
detected by cavity showed a more specific area that 
described the actual cavity as a binding site (Figure 
1). This area is the place where interactions between 
amino acid residues and receptors and ligands will 
be used as the grid box area. The selection of cavity 
binding pocket by CLC drug design based on the 
largest pocket size (Li et al., 2008) and more open 
and compact pockets have good properties for drug 
binding (Cheng et al., 2007). Ligands, receptor, and 
Autodock Vina software was saved in a folder 
located on drive C: windows in the vina folder. The 
destination was saved in one folder so that the 
docking process can be carried out through the 
command prompt. The command prompt is a 
command line interface based program with written 
work orders. At the receptor, the grid box must be 
determined according to the results of the cavity 
binding pocket from CLC Drug Design which was 
set in the offline software of Autodock Tools. The 
grid box used for 1CQE in the oriented docking 
process was at the center_x coordinate = 28,453; 
center_y = 7.271; center_z = 195.072, grid size 56 x 
40 x 122Å with a spacing of 0.375Å (Figure 2). 
Analysis of results in molecular docking includes 
values of ΔG binding affinity and Root Mean Square 
Deviation (RMSD). Molecular docking was 
conducted to see the complex conformation of the 
receptor-the docked ligand with Autodock Vina. 
Determination of ligand conformation can be seen 
from the results that come out in the command 
prompt program which will be selected one of the 
best out of nine conformations out of the docking 
results by using Autodock Vina. The docking result 
was the value of ΔG binding affinity (kcal/mol) for 
one ligand. Affinity binding is a docking parameter 
using Autodock Vina. The smaller the value of the 
ΔG binding affinity, the affinity between the 
receptor - the ligand will be higher and otherwise, the 
greater the value of ΔG binding affinity, the affinity 
between receptor-ligand complex will be lower 
(Rachmania et al., 2015). 
Table 1: Results of standard ligand docking (Aspirin), 
lemon plant ligand with COX-1 receptor (1CQE) using 
Autodock Vina Software. 
Ligands ΔG Binding Affinity (kcal/mol) 
RMSD 
(Å)
Aspirin -6.5 0
Neohesperidin -15.4 0
Rutin -15.3 0
Eriocitrin -14.9 0
Hesperidin -14.7 0
Diosmin -14.1 0
Luteolin -10.0 0
Nobiletin -9.5 0
Sinensetin -9.5 0
Tangeritin -9.5 0 
Figure 2: Results of COX-1 receptor site binding detection (CLC Drug Discovery Software And Autodock Tools). 
Description: The area in the blue box is the actual cavity as a binding site on the COX-1 receptor. 
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 Based on table 1, it can be seen that of the ten 
ligands that were analyzed, the lowest values of ΔG 
binding affinity in lemon are neohesperidin -15.4 
kcal/mol and rutin -15.3 kcal/mol. The ΔG binding 
value of affinity aspirin as a standard ligand is -6.5 
kcal/mol. These values suggest that neohesperidin 
and rutin ligands have better affinity than aspirin and 
have antiplatelet potency. RMSD is the value used to 
determine whether the prediction of the bond mode 
is successful and important for validating the 
docking program with a default value of ≤ 2Å. With 
increasing deviations, the greater the error of 
predicting the ligand interaction with receptors 
(Brooijmans, 2009). The RMSD value obtained 
from the docking of each ligand in the best 
conformation is 0. This is caused by Vina compared 
the value of each conformation with its best 
conformation value. 
The interaction between the receptor and the 
ligand resulted in the distance between the bonds 
Table 2: The distance of amino acid bond and residue, ligand functional group between Aspirin, Neohesperidin, and Rutin 
with COX-1 Receptor (1CQE) using PyMol Software. 
Ligands The Distance of hydrogen bond (Å)
Amino Acid Residue 
Binding Functional groups binding 
Aspirin 2,8 Cys41 -O 
 3,4 Cys41 -O 
Neohesperidin 3,0 Arg 469 -OH 
 3,1 Arg 469 -OH 
 3,5 Gln 44 -O 
 3,3 Cys 41 -OH 
 3,4 Cys 41 -OH 
 3,2 Lys 468 -OH 
Rutin 3,4 Lys468 -OH 
 2,3 Glu465 -OH 
 3,0 Glu465 -OH 
 2,8 Asp135 -OH 
 3,2 Asp135 -OH 
 3,2 Gly45 -OH 
 3,4 Gly45 -OH 
 2,6 Cys41 -O 
 3,2 His43 -OH 
 
Figure 3. Residue contact between Neohesperidin and 1CQE receptor (Software Pymol) 
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 and the bonded amino acid residues. Hydrogen 
bonding is a bond that can occur by involving the 
interaction of hydrogen atoms bonded covalently 
with electronegative atoms such as Flour (F), 
Nitrogen (N), Oxygen (O) (Glowacki et al., 2013). 
Table 2 shows distances, amino acids and binding 
groups that illustrate the interaction between 
ligands/drugs with COX-1 receptors. The interaction 
between aspirin as a standard drug against the COX-
1 receptor shows the presence of hydrogen bonds 
from the -O group at Cys41 residues. For ligands 
having the lowest ΔG binding affinity values, 
neohesperidin and rutin, show that hydrogen bonds 
are formed from the -O and -OH groups to the 
Arg469, Gln44, Cys41, and Lys468 residues in 
neohesperidin (Figure 3). The hydrogen bonds are 
formed from the -O and -OH groups to the residues 
Glu465, Cys41, Gly45, Asp135, Lys468, and His43 
on the rutin (Figure 4). Hydrogen bonds may occur 
between intermolecular and intramolecular, a good 
range of hydrogen bonds at 2.5-3.5 Å (Syahputra et 
al., 2014). The hydrogen bond distance that occurs 
between amino acids residues in the COX-1 receptor 
and neohesperidin and the rutin is a good hydrogen 
bond because it is in the range 2.5-3.5 Å. So from 
the results of the in silico analysis using molecular 
docking method, it can be concluded that 
neohesperidin and rutin compounds in lemon are 
predicted to have potential as antiplatelet ischaemic 
in stroke. 
4 CONCLUSIONS 
The flavonoid derived compounds found in lemon 
(Citrus limon (Linn) Burm f) ie neohesperidin and 
rutin result values of ΔG binding affinity (kcal/mol), 
i.e. -15.4 kcal/mol and -15.3 kcal/mol. These 
numbers are lower compared with aspirin 
comparative drugs that has a value of ΔG binding 
affinity -6.5 kcal/mol. neohesperidin and rutin 
compounds have a better affinity than aspirin so that 
it can be used as an antiplatelet candidate in 
ischaemic stroke disease. 
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